Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Sucampo Pharma shares viewed as undervalued at Mizuho ahead of the March 8 4Q:16 report; reits Buy rating and $16 tgt (11.71 -0.14)Mizuho thinks near-term Amitiza outlook remains favorable but expects minimal catalyst flow in 2017. The interim futility analysis of the CPP-1X/Sulindac trial in the treatment of familial adenomatous polyposis (FAP), an orphan disease leading to excessive polyp growth and cancer in the colon is expected in mid-2017. The firm models a 30% probability of success.</td> </tr></table>"